Jun Yan, M.D., Ph.D.


M.D., Jiangsu University School of Medicine, China 1985
M.S., Immunology, Nanjing Medical University, China 1991
Ph.D., Immunology, Shanghai Jiaotong University School of Medicine, China 1997
Postdoctoral Fellowship, Department of Pathology, University of Louisville, USA 1997-1999
Research Associate, Department of Internal Medicine, Yale University School of Medicine 1999-2002

Curriculum Vitae

Current Positions:

Professor of Surgery, Microbiology and Immunology, and Pharmacology and Toxicology
Endowed Chair in Translational Research, James Graham Brown Cancer Center
Director, Division of Immunotherapy, UofL School of Medicine

Contact Information:

Clinical Translational Research Building, Room 319
University of Louisville
505 Hancock St.
Louisville, KY 40202, USA
Phone 502-852-3628
Fax 502-852-2123
Email: jun.yan@louisville.edu


Research Description

Dr. Yan’s current major research interests are to understand the cellular and molecular mechanisms by which yeast-derived polysaccharide b-glucan modulates immunosuppressive myeloid cells to enhance antitumor immunotherapy using mouse tumor models and human cancer patients. In addition, this laboratory has recently discovered that gdT cells are the major cellular source of inflammatory cytokine IL-17 in psoriatic skin lesions and human colon cancer. This line of research investigates the roles of innate gdT cells in health and diseases. They are interested in gdT17 cell development, metabolism, and signaling pathways that regulate their activation and function.  The third major area of interest in Dr. Yan’s laboratory involves the roles of B-cells in the regulation of autoreactive T-cell activation and tolerance using a murine systemic lupus erythematosus (SLE) model as well as human lung cancer.  They are interested in B cell repertoire and how T-B cell collaboration in cancer shapes antitumor T-cell response. Knowledge gained from these studies has led them to develop effective vaccines for cancer and autoimmune diseases.

Representative Publications:

γδT17 in skin inflammation and human colon cancer

  • Fleming C, Cai Y, Sun X, Venkatakrishna J, Xue F, Morrissey S, Wei YL, Chien YH, Zhang HG, Haribabu B., Huang J, Yan J.  Microbiota activated CD103+ DCs stemming from microbiota adaption specifically drive γδT17 proliferation and activation.  Microbiome 2017Apr 24;5(1):46. PMID: 28438184. PMCID: 5404689.
  • Fleming C, Morrissey S, Cai Y, Yan J.  γδT Cells: Unexpected regulators of cancer development and progression.  Trends in Cancer 2017 Aug;3(8):561-70. PMID: 28780933. PMCID: PMC5551453.
  • Cai YH, Xue F, Fleming C, Yang J, Ding C, Ma Y, Liu M, Zhang HG, Zheng J, Xiong N, Yan J.  Differential developmental requirement and peripheral regulation for dermal Vg4 and Vg6T17 cells in health and inflammation.  Nature Communications 2014 Jun 9;5:3986. doi: 10.1038/ncomms4986. PMID: 24909115. PMCID: 4068267.
  • Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W, Chen Z, Wang K, Zhang T, Xu J, Han Y, Zhang T, Wu X, Wang J, Gong W, Zheng S, Qiu F, Yan J*,Huang J*.  γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer.  Immunity 2014;40:785-800. PMID: 24801835. PMCID: PMC4716654. (*Corresponding authors)
  • Cai YH, Shen XY, Ding CL, Qi CJ, Li KJ, Li X, Jala VR, Zhang HG, Wang T, Zheng J, Yan J.   Pivotal role of dermal IL-17-producing γδT cells in skin inflammation.  Immunity 2011;35(4):596-610. PMID: 21982596. PMCID: PMC3025267.

b-Glucan-mediated cancer immunotherapy

  • Albeituni SH, Ding C, Liu M, Hu X, Luo F, Kloecker G, Bousamra M 2nd, Zhang HG, Yan J.  Yeast-derived particulate b-glucan treatment subverts the suppression of myeloid-derived suppressor cells (MDSC) by inducing polymorphonuclear-MDSC apoptosis and monocytic MDSC differentiation to APC in cancer.  Journal of Immunology 2016 Mar 1;196(5):2167-80. PMID: 26810222. PMCID: PMC4761495.
  • Liu M, Luo F, Ding C, Albeituni S, Hu X, Ma Y, Cai Y, McNally L, Sanders M, Jain D, Kloecker G, Bousamara M, Zhang HG, Higashi R, Lane AN, Fan TWM, Yan J.  Dectin-1 activation by a natural product β-glucan converts immunosuppressive macrophages into an M1 phenotype.  Journal of Immunology 2015 Nov 15;195(10):5055-65. PMID:26453753. PMCID: PMC4637216.
  • Sellers K, Fox MP, Bousamara M, Slone SP, Higashi R, Miller DM, Wang Y, Yan J, Yuneva MO, Deshpande R, Lane AN, Fan TW.  Pyruvate carboxylase is critical for non-small cell lung cancer proliferation.  Journal of Clinical Investigation 2015 Feb 2;125(2):687-98. PMID: 25607840. PMCID: PMC4319441.
  • Gunn L, Ding CL, Liu M, Ma YF, Qi CJ, Cai YH, Hu XL, Aggarwal D, Zhang HG, Yan J.  Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.  Journal of Immunology 2012;189(6):2985-94. PMID: 22914051. PMCID: PMC3436956.
  • Li B, Cai YH, Qi CJ, Hansen R, Ding CL, Mitchell TC, Yan J.  Orally administrated particular b-glucan modulates tumor-capturing dendritic cells and improves anti-tumor T cell responses in cancer.  Clinical Cancer Research 2010 Nov 1;16(21):5153-64.PMID: 20855461. PMCID: PMC2970627.
  • Salvador C, Li B, Hansen R, Cramer D, Kong M, Yan, J.  Yeast-derived b-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models.  Clinical Cancer Research2008 Feb 15;14(4):1239-47. PMID: 18281559. PMCID: PMC2934864.
    • Li B, Allendorf D, Hansen R, Marroquin J, Cramer DE, Harris CL, Yan, J.  Combined yeast b-glucan and aAnti-tumor mAb therapy require C5a-mediated neutrophil chemotaxis via regulation of decay accelerating factor CD55.  Cancer Research 2007 Aug 1;67(15):7421-30. PMID: 17671212. PMCID: 1933500.
  • Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR, Yan J.  Differential pathways regulating innate and adaptive anti-tumor immune responses by particulate and soluble yeast-derived b-glucans.  Blood 2011 Jun 23;117(25):6825-36. PMID: 21531981. PMCID: 3128477.

Autoreactive B cell regulation

  • Ding C, Chen X, Dascani P, Bolli R, Zhang HG, Mcleish K, Yan J.  STAT3 signaling in B cells is critical for the germinal center maintenance and contributes to the pathogenesis of murine models of Lupus.  Journal of Immunology 2016 Jun 1;196(11):4477-86. PMID: 27183592. PMCID: PMC4875824
  • Ding C, Ma Y, Chen X, Liu M, Cai Y, Hu X, Xiang D, Nath S, Zhang HG, Ye H, Powell D, Yan J.  Integrin CD11b negatively regulates BCR signaling to maintain autoreactive B cell tolerance.  Nature Communications 2013;4:2813. doi: 10.1038/ncomms3813.  PMID: 24264377.
  • Ma Y, Xiang D, Sun J, Ding C, Liu M, Hu X, Kloecker G, Zhang H, Yan J.  Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development.  Journal of Immunology 2013 Jun 1;190(11):5588-99. PMID:23695661. PMCID: PMC3660458.
  • Ding C, Cai Y, Marroquin J, Ildstad ST, Yan J.  Plasmacytoid dendritic cells regulate autoreactive B cell activation via soluble factors and in a cell-to-cell contact manner. Journal of Immunology 2009 Dec 1;183(11):7140-9. PMID: 19890051. PMCID: PMC3351849.
  • Ding C, Wang L, Marroquin J, Yan, J.  Targeting of antigens to B cells augments antigen-specific T cell responses and breaks immune tolerance to tumor-associated antigen MUC1.  Blood 2008 Oct 1;112(7):2817-25. PMID: 18669871. PMCID: 2556617.

PubMed Information